[1]
Saeed, M.; Faisal, S.M.; Akhtar, F.; Ahmad, S.; Alreshidi, M.M.; Kausar, M.A.; Kazmi, S.; Saeed, A.; Adnan, M.; Ashraf, G.M. Human papillomavirus induced cervical and oropharyngeal cancers: from mechanisms to potential immuno-therapeutic strategies. Curr. Drug Metab., 2020, 21(3), 167-177.
[http://dx.doi.org/10.2174/1389200221666200421121228]
[http://dx.doi.org/10.2174/1389200221666200421121228]
[2]
Kamal, M.A.; Al-Zahrani, M.H.; Khan, S.H.; Khan, M.H.; Al-Subhi, H.A.; Kuerban, A.; Aslam, M.; Al-Abbasi, F.A.; Anwar, F. Tubulin proteins in cancer resistance: a review. Curr. Drug Metab., 2020, 21(3), 178-185.
[http://dx.doi.org/10.2174/1389200221666200226123638]
[http://dx.doi.org/10.2174/1389200221666200226123638]
[3]
Chavda, V.; Patel, V.; Yadav, D.; Shah, J.; Patel, S.; Jin, J-O. Therapeutics and research related to glioblastoma: advancements and future targets. Curr. Drug Metab., 2020, 21(3), 186-198.
[http://dx.doi.org/10.2174/1389200221666200408083950]
[http://dx.doi.org/10.2174/1389200221666200408083950]
[4]
Shafi, S.; Khan, S.; Hoda, F.; Fayaz, F.; Singh, A.; Khan, M.A.; Ali, R.; Pottoo, F.H.; Tariq, S.; Najmi, A.K. Decoding novel mechanisms and emerging therapeutic strategies in breast cancer resistance. Curr. Drug Metab., 2020, 21(3), 199-210.
[http://dx.doi.org/10.2174/1389200221666200303124946]
[http://dx.doi.org/10.2174/1389200221666200303124946]
[5]
Kancharla, J.; Devi , VPI; Lakkakula , BV; Veera , BP; Afroz, A. Meta-analysis of NFKB1 -94 ATTG ins/del polymorphism and risk of breast cancer. Curr. Drug Metab., 2020, 21(3), 221-225.
[http://dx.doi.org/10.2174/1389200221666200310113118]
[http://dx.doi.org/10.2174/1389200221666200310113118]
[6]
Durthi, C.P.; Pola, M.; Rajulapati, S.B.; Kola, A.K. Insights into potent therapeutical antileukemic agent L-glutaminase enzyme under solid-state fermentation: A review. Curr. Drug Metab., 2020, 21(3), 211-220.
[http://dx.doi.org/10.2174/1389200221666200421122147]
[http://dx.doi.org/10.2174/1389200221666200421122147]